



Company Overview

CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

CohBar Reports Second Quarter 2019 Financial Results and Business Update

Aug 7 2019, 4:05 PM EDT

CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019

Jul 31 2019, 4:05 PM EDT

CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions

Jun 10 2019, 9:00 AM EDT

Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	57.94m
Last Price	\$1.45
52-Week	\$1.24 - \$4.9199

09/13/2019 04:00 PM EDT

Investor Relations

Jon Stern, COO
Investor Relations
T: (650) 446-7888
jon.stern@cohbar.com

Management Team

Steven B. Engle, M.S.

Chief Executive Officer, Director

Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

Jon L. Stern, MBA

Chief Operating Officer, Director

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.